[go: up one dir, main page]

FR22C1059I1 - Proteines de liaison a l'antigene capable de se lier a la lymphopoietine stromale thymique - Google Patents

Proteines de liaison a l'antigene capable de se lier a la lymphopoietine stromale thymique

Info

Publication number
FR22C1059I1
FR22C1059I1 FR22C1059C FR22C1059C FR22C1059I1 FR 22C1059 I1 FR22C1059 I1 FR 22C1059I1 FR 22C1059 C FR22C1059 C FR 22C1059C FR 22C1059 C FR22C1059 C FR 22C1059C FR 22C1059 I1 FR22C1059 I1 FR 22C1059I1
Authority
FR
France
Prior art keywords
binding
antigen
proteins capable
thymic stromal
stromal lymphopoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1059C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40242598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1059(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FR22C1059I1 publication Critical patent/FR22C1059I1/fr
Application granted granted Critical
Publication of FR22C1059I2 publication Critical patent/FR22C1059I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR22C1059C 2007-09-10 2022-12-12 Proteines de liaison a l'antigene capable de se lier a la lymphopoietine stromale thymique Active FR22C1059I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10
US9167608P 2008-08-25 2008-08-25
PCT/US2008/010510 WO2009035577A1 (fr) 2007-09-10 2008-09-09 Protéines de liaison à l'antigène capable de se lier à la lymphopoïétine stromale thymique

Publications (2)

Publication Number Publication Date
FR22C1059I1 true FR22C1059I1 (fr) 2023-02-03
FR22C1059I2 FR22C1059I2 (fr) 2023-12-22

Family

ID=40242598

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1059C Active FR22C1059I2 (fr) 2007-09-10 2022-12-12 Proteines de liaison a l'antigene capable de se lier a la lymphopoietine stromale thymique

Country Status (36)

Country Link
US (5) US7982016B2 (fr)
EP (3) EP3524622A1 (fr)
JP (8) JP5956716B2 (fr)
KR (2) KR20140141666A (fr)
CN (2) CN101809035B (fr)
AR (1) AR068508A1 (fr)
AU (1) AU2008300028B2 (fr)
CA (1) CA2698382C (fr)
CL (2) CL2008002668A1 (fr)
CR (2) CR11319A (fr)
CY (2) CY1117702T1 (fr)
DK (1) DK2205635T3 (fr)
EA (2) EA022796B1 (fr)
ES (1) ES2581229T3 (fr)
FR (1) FR22C1059I2 (fr)
HK (1) HK1145843A1 (fr)
HR (1) HRP20160638T1 (fr)
HU (2) HUE028361T2 (fr)
IL (3) IL204069A (fr)
JO (1) JO3351B1 (fr)
LT (1) LT2205635T (fr)
MX (1) MX2010002590A (fr)
MY (1) MY150242A (fr)
NL (1) NL301207I2 (fr)
NO (1) NO2022055I1 (fr)
NZ (1) NZ583933A (fr)
PE (2) PE20110668A1 (fr)
PH (1) PH12017501025B1 (fr)
PL (1) PL2205635T3 (fr)
PT (1) PT2205635T (fr)
RS (1) RS54950B1 (fr)
SG (2) SG10201506251YA (fr)
SI (1) SI2205635T1 (fr)
TW (2) TW201412774A (fr)
WO (1) WO2009035577A1 (fr)
ZA (1) ZA201001895B (fr)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
CA2711826C (fr) 2008-01-25 2018-02-27 Amgen Inc. Anticorps anti-ferroportine et procedes d'utilisation
PE20121646A1 (es) 2009-11-04 2012-12-02 Merck Sharp & Dohme Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
JP6159660B2 (ja) * 2010-09-22 2017-07-05 アムジエン・インコーポレーテツド 担体としての免疫グロブリンおよびその使用
EP2773774A4 (fr) * 2011-11-03 2015-06-10 Merck Sharp & Dohme Biomarqueurs pour le traitement de tslp
PL3431492T3 (pl) * 2012-04-27 2021-07-05 Novo Nordisk A/S Białka wiążące antygen ludzkiego ligandu CD30
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3712166A1 (fr) 2013-09-05 2020-09-23 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
WO2015118124A1 (fr) * 2014-02-06 2015-08-13 Vib Vzw Antagoniste du récepteur de la lymphopoïétine stromale thymique
WO2015171777A1 (fr) 2014-05-07 2015-11-12 Amgen Inc. Auto-injecteur comprenant des éléments de réduction de choc
MX2016014761A (es) 2014-05-16 2017-05-25 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
CN113990437A (zh) 2014-06-03 2022-01-28 安姆根有限公司 用于远程处理由药物递送装置收集的数据的系统和方法
EP3206739B1 (fr) 2014-10-14 2021-12-01 Amgen Inc. Dispositif d'injection de médicament comportant des témoins visuels et sonores
SG11201703152RA (en) 2014-10-23 2017-05-30 Amgen Inc Reducing viscosity of pharmaceutical formulations
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
MX2017010466A (es) 2015-02-17 2018-06-06 Amgen Inc Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas.
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
CA2978026A1 (fr) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Proteines de liaison a la tslp
BR112017024899A2 (pt) * 2015-05-21 2018-11-13 Harpoon Therapeutics, Inc. proteínas de ligação trispecíficas e métodos de uso.
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
AU2016320748B2 (en) * 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
SI3347377T1 (sl) 2015-09-09 2021-06-30 Novartis Ag Protitelesa, ki vežejo timusni stromalni limfopoietin (tslp) in postopki uporabe protiteles
EP3386573B1 (fr) 2015-12-09 2019-10-02 Amgen Inc. Auto-injecteur avec capuchon de signalisation
WO2017120178A1 (fr) 2016-01-06 2017-07-13 Amgen Inc. Auto-injecteur pourvu d'une électronique de signalisation
AU2017209083A1 (en) 2016-01-22 2018-07-12 Adimab, Llc Anti-coagulation factor XI antibodies
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
EP4035711A1 (fr) 2016-03-15 2022-08-03 Amgen Inc. Réduction de la probabilité de rupture de verre dans des dispositifs d'administration de médicament
KR20180132766A (ko) * 2016-04-05 2018-12-12 브이아이비 브이지더블유 신규한 ｔｓｌｐ 저해인자
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142B1 (fr) 2016-05-13 2023-08-09 Amgen Inc. Ensemble manchon de flacon
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (fr) 2016-06-03 2019-04-10 Amgen Inc. Appareils et procédés d'essai au choc destinés aux dispositifs d'administration de médicaments
BR112018075858A2 (pt) 2016-06-14 2019-04-02 Merck Sharp & Dohme Corp. anticorpos anti-fator xi de coagulação
WO2018004842A1 (fr) 2016-07-01 2018-01-04 Amgen Inc. Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
CA3032806C (fr) * 2016-08-05 2021-04-27 Y-Biologics Inc. Anticorps dirige contre le ligand 1 de mort programmee (pd-l1) et son utilisation
WO2018034784A1 (fr) 2016-08-17 2018-02-22 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement.
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
PE20191208A1 (es) 2017-01-24 2019-09-10 I Mab Anticuerpos anti-cd73 y usos de los mismos
CA3048520A1 (fr) 2017-02-17 2018-08-23 Amgen Inc. Dispositif d'administration de medicament a trajet d'ecoulement de fluide sterile et procede d'assemblage associe
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
MX2019010544A (es) 2017-03-06 2019-10-21 Amgen Inc Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
EP3592402A1 (fr) 2017-03-07 2020-01-15 Amgen Inc. Insertion d'aiguille par surpression
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc Sistema y metodo para conjunto de jeringa y vastago de embolo.
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MA48464A (fr) 2017-04-28 2020-03-04 Amgen Inc Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
WO2018226515A1 (fr) 2017-06-08 2018-12-13 Amgen Inc. Ensemble de seringue d'un appareil d'administration de médicament et procédé d'assemblage
CA3066399A1 (fr) 2017-06-08 2018-12-13 Amgen Inc. Dispositif d'administration de medicament entraine par couple
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
CA3063921A1 (fr) 2017-06-23 2018-12-27 Amgen Inc. Dispositif electronique d'administration de medicament comprenant un bouchon active par un ensemble commutateur
CN109206514B (zh) * 2017-07-03 2019-10-08 拜西欧斯（北京）生物技术有限公司 Tslp单克隆抗体及其制备方法和应用
ES2972207T3 (es) 2017-07-14 2024-06-11 Amgen Inc Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing element for drug container and methods of assembly
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
EP3662287B1 (fr) 2017-08-01 2024-02-28 Amgen Inc. Systèmes et procédés de préparation d'échantillon polypeptides en temps réel pour anaylse par spectroscopie de masse
CA3071636A1 (fr) 2017-08-01 2019-02-07 Amgen Inc. Systemes et procedes pour effectuer un dosage du glycane en temps reel d'un echantillon
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3669004A1 (fr) 2017-08-16 2020-06-24 Medimmune, LLC Compositions et méthodes pour le traitement de la dermatite atopique et la sélection du traitement
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (fr) 2017-10-06 2023-11-29 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019090086A1 (fr) 2017-11-03 2019-05-09 Amgen Inc. Systèmes et approches pour stériliser un dispositif d'administration de médicament
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
WO2019094138A1 (fr) 2017-11-10 2019-05-16 Amgen Inc. Pistons pour dispositifs d'administration de médicament
CN111278487B (zh) 2017-11-16 2022-06-24 安进公司 用于药物递送装置的门闩锁机构
JP2021516672A (ja) 2018-03-13 2021-07-08 アムジエン・インコーポレーテツド 質量分光測定分析のためのトリプシン耐性ポリペプチドを調製するための方法
IL277106B2 (en) 2018-03-13 2024-03-01 Amgen Inc Sequential digestion of polypeptides for mass spectrometric analysis
AU2019243848B2 (en) 2018-03-26 2025-01-02 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US20210128844A1 (en) 2018-07-24 2021-05-06 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023444A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de médicaments
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020068623A1 (fr) 2018-09-24 2020-04-02 Amgen Inc. Systèmes et procédés de dosage interventionnel
CA3114038A1 (fr) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Proteines de liaison a dll3 et methodes d'utilisation
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
IL281712B2 (en) 2018-10-02 2025-03-01 Amgen Inc Injection systems for drug delivery with internal power transmission
AU2019355979B2 (en) 2018-10-05 2024-12-05 Amgen Inc. Drug delivery device having dose indicator
IL281894B2 (en) 2018-10-15 2024-12-01 Amgen Inc Drug delivery device having damping mechanism
AR116703A1 (es) 2018-10-15 2021-06-02 Amgen Inc Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091981A1 (fr) 2018-11-01 2020-05-07 Amgen Inc. Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
EP3873566B1 (fr) 2018-11-01 2024-11-27 Amgen Inc. Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
WO2020124008A1 (fr) 2018-12-14 2020-06-18 Amgen Inc. Procédé d'adéquation de système destiné à être utilisé avec une détermination de concentration de protéine par pente
US11452738B2 (en) 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
JP7483731B2 (ja) 2019-02-14 2024-05-15 アムジエン・インコーポレーテツド 試料の調製及びその試料のリアルタイムアッセイの実施のためのシステム及び方法
WO2020172293A1 (fr) 2019-02-20 2020-08-27 Amgen Inc. Procédés de détermination de la stabilité de protéines
EP3935396A1 (fr) 2019-03-04 2022-01-12 Amgen Inc. Réversibilité in vivo d'espèces à poids moléculaire élevé
US12078701B2 (en) 2019-03-27 2024-09-03 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
EP3981788A4 (fr) 2019-06-04 2023-03-22 Jiangsu Hengrui Medicine Co., Ltd. Anticorps capable de se lier à la lymphopoïétine stromale thymique et son utilisation
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
BR112022008031A2 (pt) 2019-10-28 2022-07-12 Medimmune Ltd Formulações de pó seco de anticorpos de ligação à linfopoietina estromal tímica (tslp) e métodos de uso das mesmas
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
JP2023505408A (ja) * 2019-12-13 2023-02-09 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ｔｓｌｐ抗体及びその使用
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
US20230073888A1 (en) 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
CR20220457A (es) 2020-02-13 2023-01-09 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
MX2022010120A (es) 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN111662379B (zh) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗新型冠状病毒的抗体、制备方法和应用
JP2023526469A (ja) * 2020-05-20 2023-06-21 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ＳＡＲＳ－ＣｏＶ－２に対する強力な中和抗体、その生成および使用
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3195365A1 (fr) 2020-09-18 2022-03-24 Amgen Inc. Procedes de traitement d'un echantillon pour analyse de cartographie peptidique
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
JP2023549113A (ja) 2020-11-05 2023-11-22 アムジエン・インコーポレーテツド タンパク質を処理するための材料及び方法
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
TW202229339A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 結合胸腺基質淋巴細胞生成素的抗體及其應用
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
WO2022166739A1 (fr) * 2021-02-04 2022-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Anticorps reconnaissant spécifiquement la lymphopoïétine stromale thymique et leurs utilisations
IL307439A (en) 2021-04-23 2023-12-01 Amgen Inc Different anti-TSLP antibodies
EP4326766A1 (fr) 2021-04-23 2024-02-28 Amgen Inc. Compositions d'anticorps anti-tslp et leurs utilisations
EP4341161A1 (fr) 2021-05-21 2024-03-27 Amgen Inc. Procédé d?optimisation d?une recette de remplissage pour un récipient de médicament
JP2024520873A (ja) * 2021-05-30 2024-05-24 バイオロジック デザイン リミテッド 操作された二重結合抗体およびその使用
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
EP4352094A1 (fr) 2021-06-07 2024-04-17 Amgen Inc. Utilisation de fucosidase pour contrôler le taux d'afucosylation de protéines glycosylées
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
MX2024003852A (es) 2021-10-05 2024-05-24 Amgen Inc Unión al receptor fc-gamma y contenido de glucanos.
WO2023070948A1 (fr) * 2021-11-01 2023-05-04 江苏荃信生物医药股份有限公司 Procédé de préparation d'une solution concentrée contenant un anticorps monoclonal anti-lymphopoïétine stromale thymique humaine (tslp), et préparation liquide
WO2023086793A1 (fr) 2021-11-09 2023-05-19 Amgen Inc. Production de protéines thérapeutiques
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用
WO2023116925A1 (fr) * 2021-12-24 2023-06-29 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Nouveaux anticorps anti-tslp
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
CN118580343A (zh) * 2022-10-21 2024-09-03 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
WO2024174895A1 (fr) * 2023-02-23 2024-08-29 四川科伦博泰生物医药股份有限公司 Préparation d'anticorps monoclonaux ciblant la tslp
WO2024220916A1 (fr) 2023-04-20 2024-10-24 Amgen Inc. Procédés de détermination de teneur relative en glycane non apparié
WO2024238877A1 (fr) 2023-05-18 2024-11-21 Medimmune, Llc Traitement de l'asthme dépendant des corticostéroïdes avec un anticorps anti-tslp
WO2024259275A1 (fr) 2023-06-14 2024-12-19 Bristol-Myers Squibb Company Quantification en temps quasi réel d'acide sialique de glycoprotéines
WO2024264003A2 (fr) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Anticorps se liant à l'interleukine 13 et à la tslp ou à la tslpr, et procédés d'utilisation
WO2025038600A1 (fr) 2023-08-14 2025-02-20 Amgen Inc. Procédés de réduction de couleur jaune
WO2025049345A1 (fr) 2023-08-25 2025-03-06 Proteologix Us Inc. Constructions d'anticorps multispécifiques anti-il-13 et leurs utilisations

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990015870A1 (fr) 1989-06-15 1990-12-27 Immunex Corporation Recepteurs d'interleukine-7
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2090126C (fr) 1990-08-02 2002-10-22 John W. Schrader Methodes de production de proteines dotees d'une fonction desiree
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (fr) 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0639079B1 (fr) 1992-04-30 2000-01-12 Amgen Inc. Methodes de traitement des maladies induites par l'interleukine-1 et le facteur de necrose tumorale
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
EP0737071A1 (fr) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Oligodesoxynucleotide anti-sens inhibant les cytokines fibrogenes, et son utilisation
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO1998056915A2 (fr) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6844170B1 (en) 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999047538A1 (fr) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Analogue de chaine gamma commune de recepteur de cytokine
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2343979C (fr) 1998-09-21 2011-11-15 Schering Corporation Interleukine humaine b50, ses utilisations therapeutiques
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
AU2396600A (en) 1998-12-30 2000-07-31 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
EP1712239A3 (fr) 2000-05-12 2007-08-22 Immunex Corporation Inhibiteurs d'interleukine 1 dans le traitement de maladies
JP2004519205A (ja) 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
US6955895B2 (en) 2000-06-28 2005-10-18 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
EP1417231B1 (fr) 2001-07-23 2013-06-19 Immunex Corporation Lymphopoietine thymique stromale (tslp) humaine modifiee
US20030186875A1 (en) 2002-02-01 2003-10-02 Rene De Waal Malefyt Uses of mammalian cytokine; related reagents
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
ES2313076T3 (es) 2003-07-18 2009-03-01 Schering Corporation Tratamiento y diagnostico de neoplasias usando linfopoyetina estromal timica.
ES2523837T3 (es) 2003-07-18 2014-12-01 Amgen Inc. Agentes de unión específica al factor de crecimiento de hepatocitos
MXPA06006985A (es) 2003-12-19 2006-08-31 Genentech Inc Fragmentos de anticuerpo monovalente utiles como terapueticos.
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2006023791A2 (fr) 2004-08-20 2006-03-02 Amgen Inc. Procedes et compositions pour le traitement d'inflammation allergique
JP2008520684A (ja) * 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
RU2486202C2 (ru) 2006-01-13 2013-06-27 Айрм Ллк Антитела к рецептору тимусного стромального лимфопоэтина
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
CN102027012A (zh) 2007-06-20 2011-04-20 Irm责任有限公司 用于治疗变应性疾病的方法和组合物
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
JP2015091820A (ja) 2015-05-14
CN101809035A (zh) 2010-08-18
SG178781A1 (en) 2012-03-29
PH12017501025B1 (en) 2022-10-26
AR068508A1 (es) 2009-11-18
PE20110668A1 (es) 2011-10-01
JP2023065375A (ja) 2023-05-12
NZ583933A (en) 2012-07-27
NL301207I2 (nl) 2023-02-02
JP2021191758A (ja) 2021-12-16
JP2019038843A (ja) 2019-03-14
EA201590631A1 (ru) 2016-03-31
SI2205635T1 (sl) 2016-09-30
CY2022036I1 (el) 2023-01-05
KR20140141666A (ko) 2014-12-10
MY150242A (en) 2013-12-31
US20090238823A1 (en) 2009-09-24
AU2008300028A1 (en) 2009-03-19
CL2008002668A1 (es) 2009-08-14
EP2703414A1 (fr) 2014-03-05
CY2022036I2 (el) 2023-03-24
PL2205635T3 (pl) 2016-12-30
LT2205635T (lt) 2016-09-26
TW201412774A (zh) 2014-04-01
WO2009035577A1 (fr) 2009-03-19
CN104231081B (zh) 2022-01-11
US7982016B2 (en) 2011-07-19
US20120190829A1 (en) 2012-07-26
EP3524622A1 (fr) 2019-08-14
EP2205635B1 (fr) 2016-05-25
AU2008300028B2 (en) 2014-12-18
PH12017501025A1 (en) 2018-01-29
NL301207I1 (nl) 2022-12-21
SG10201506251YA (en) 2015-11-27
HUS2200051I1 (hu) 2022-12-28
JP2024161358A (ja) 2024-11-19
CN104231081A (zh) 2014-12-24
CN101809035B (zh) 2014-07-09
CR20150095A (es) 2015-04-06
CY1117702T1 (el) 2017-05-17
KR101597371B1 (ko) 2016-02-26
ES2581229T3 (es) 2016-09-02
US20110274687A1 (en) 2011-11-10
RS54950B1 (sr) 2016-11-30
CA2698382A1 (fr) 2009-03-19
CL2012003245A1 (es) 2013-03-22
IL204069A (en) 2017-03-30
NO2022055I1 (no) 2022-12-09
JP2020058365A (ja) 2020-04-16
PT2205635T (pt) 2016-07-13
US20160152700A1 (en) 2016-06-02
ZA201001895B (en) 2011-02-23
US10287348B2 (en) 2019-05-14
EP2205635A1 (fr) 2010-07-14
JP2017110011A (ja) 2017-06-22
IL250900A0 (en) 2017-04-30
KR20100067660A (ko) 2010-06-21
HUE028361T2 (en) 2016-12-28
CA2698382C (fr) 2015-07-14
CR11319A (es) 2010-04-21
US9284372B2 (en) 2016-03-15
DK2205635T3 (en) 2016-07-18
IL265854A (en) 2019-06-30
US20200071393A1 (en) 2020-03-05
TW200918554A (en) 2009-05-01
JO3351B1 (ar) 2019-03-13
FR22C1059I2 (fr) 2023-12-22
EA201000471A1 (ru) 2010-10-29
JP2010538608A (ja) 2010-12-16
TWI449709B (zh) 2014-08-21
HK1145843A1 (zh) 2011-05-06
EA022796B1 (ru) 2016-03-31
HRP20160638T1 (hr) 2016-07-01
MX2010002590A (es) 2010-03-26
JP5956716B2 (ja) 2016-07-27
PE20140232A1 (es) 2014-02-28
US8163284B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
FR22C1059I1 (fr) Proteines de liaison a l'antigene capable de se lier a la lymphopoietine stromale thymique
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
EP2064336A4 (fr) Proteines de liaison interleukine 13
CY2016023I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9 (pcsk9)
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0922505A2 (pt) proteínas de ligação a receptor cgrp humano
EP2126092A4 (fr) Protéines de fusion se liant aux facteurs de croissance
BRPI0815368A2 (pt) "proteinas c-fms humanas a antigeno"
ZA200901561B (en) Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
BRPI0820543A2 (pt) Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
BRPI0920027A2 (pt) isolamento e purificação de anticorpos usando cromatografia de afinidade a proteína a
IL199725A (en) Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses
EP1981538A4 (fr) Proteines de liaison a la metalloproteinase
LTC1940465I2 (lt) Naujas anti-IL-1 beta antikūnų panaudojimas
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
ATE472317T1 (de) Kosmetische verwendung von molkeproteinmizellen
EP2039704A4 (fr) Anticorps monoclonal capable de se lier au facteur de croissance de type facteur de croissance epidermique se liant a l'heparine
FR2925312B1 (fr) Utilisation cosmetique de proteines de type desmogleine i
IL186385A0 (en) Antibodies and molecules derived therefrom that bind to 161p2f10b proteins
DK1833495T3 (da) Dermatologisk anvendelse af mælkeproteiner
FR2924614B1 (fr) Utilisation cosmetique de proteines de type calgranuline a.
FR2925314B1 (fr) Utilisation cosmetique de proteines de type transglutaminase 3
EP2185724A4 (fr) Régulateurs de repliement de protéine et de neuroprotection et procédé d'utilisation
EP2024516A4 (fr) Proteines de perforine-2
EP2294090A4 (fr) Clya non hémolytique pour l'excrétion de protéines